Is Alnylam publicly traded?
When did Alnylam go public? Alnylam started trading publicly in May 2004.
Who is Dr John Maraganore?
Dr. John Maraganore is a Senior Advisor at General Atlantic, providing strategic support and advice to the firm’s investment teams and portfolio companies in the Life Sciences sector. Since 2002, Dr. Maraganore has served as the CEO of Alnylam, a biopharmaceutical company focused on RNAi therapeutics.
Is Alnylam a good investment?
Valuation metrics show that Alnylam Pharmaceuticals, Inc. may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of ALNY, demonstrate its potential to underperform the market.
Who bought Alnylam?
In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company’s drugs for $700 million.
Is Alnylam a good company?
Alnylam Pharmaceuticals is a great company to work for. It is consistently ranked as one of the top companies to work for in Boston. The company is located in Cambridge Massachusetts right by the Kendall/MIT stop.
Where is Alnylam Pharmaceuticals located?
Cambridge, Massachusetts
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Is Alnylam a biotech?
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts….Alnylam Pharmaceuticals.
| Type | Public |
|---|---|
| Website | alnylam.com |
Is Alny a buy?
(ALNY) – Zacks….(Delayed Data from NSDQ)
| Zacks Rank | Definition | Annualized Return |
|---|---|---|
| 1 | Strong Buy | 25.60% |
| 2 | Buy | 19.21% |
| 3 | Hold | 10.85% |
| 4 | Sell | 6.62% |
Is Alnylam a rare disease company?
Alnylam Publishes Its 1st-Ever Rare Disease Trend Report | Alnylam® Newsroom.
Is Alnylam a private company?
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases….Alnylam Pharmaceuticals.
| Type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 2002 |
| Headquarters | Cambridge, Massachusetts, US |
| Key people | John Maraganore, (CEO) |
Where is Alnylam based?
Is the Alnylam stock paying a dividend?
ALNY is not currently paying a regular dividend. The total number of shares of a security that have been sold short and not yet repurchased. Percentage change in short interest from the previous report to the most recent report.
When does Alnylam Pharmaceuticals ( ALNY ) report earnings?
Alnylam (ALNY) misses Q2 estimates for earnings but beats the same for sales. The company raises revenue guidance for 2021. ALNY earnings call for the period ending June 30, 2021.
What does restricted stock mean for Alnylam stock?
Restricted stock typically is that issued to company insiders with limits on when it may be traded. A company’s dividend expressed as a percentage of its current stock price. ALNY is not currently paying a regular dividend. The total number of shares of a security that have been sold short and not yet repurchased.
What kind of diseases does Alnylam Pharmaceuticals treat?
In addition to FDA-approved patisiran (Onpattro) for amyloidosis and givosiran (Givlaari) for acute hepatic porphyria, Alnylam has several partnered several pipeline candidates in rare genetic diseases, liver diseases, and other indications as well. Up-front fees from research partnerships with firms such as R